Prognostic Value of the Marker P63 in Adenocarcinoma of Lung, Breast, and Pancreas

Study Overview
=================
Brief Summary
-----------------
The p63 gene is a recently discovered member of the p53 family located at chromosome 3q27Many studies have reported that overexpression of p63 can mimic p53 activities by binding DNA, activating transcription, and inducing apoptosis. Various studies proved p63 as a marker of basal cells in normal salivary glands, breast, prostate, respiratory and squamous epithelia, and of tumor cells from various malignancies. Still, p63 has been the subject of relatively few studies in lung adenocarcinoma, and breast carcinoma, and no study has described the correlation of p63 with pancreatic ductal adenocarcinoma. In the current study, we aim to evaluate the prognostic value of the expression of p63 in the lung adenocarcinoma, breast adenocarcinoma, and pancreatic ductal adenocarcinoma. We will achieve this aim by collecting clinical data retrospectively from the patients' medical records as well as assessing the histological sections and performing immunohistochemical staining for p63.

Official Title
-----------------
Prognostic Value of Quantitative p63 Immunostaining in Adenocarcinoma of Lung, Breast, and Pancreas

Conditions
-----------------
Lung Adenocarcinoma, Breast Adenocarcinoma, Pancreatic Ductal Adenocarcinoma

Intervention / Treatment
-----------------
* Other: their will be no intervention in any of the groups, the study is retrospective


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who were treated at our institution for lung adenocarcinoma, breast adenocarcinoma, or pancreatic ductal adenocarcinoma. Available histopathological diagnosis of the malignancy. Exclusion Criteria: Patients with inoperable tumors. Patients with second primary tumor. Patients with pathological blocks not enough for future slicing.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Lung adenocarcinoma<br>This group will include 100 patients with lung adenocarcinoma, the clinical outcomes will be retrospectively assessed. at the same time 2 histopathological slides will be retrieved and stained for known markers as well as to P63. | Other: their will be no intervention in any of the groups, the study is retrospective<br> <br> |
| Breast adenocarcinoma<br>This group will include 100 patients with breast adenocarcinoma, the clinical outcomes will be retrospectively assessed. at the same time 2 histopathological slides will be retrieved and stained for known markers as well as to P63. | Other: their will be no intervention in any of the groups, the study is retrospective<br> <br> |
| Pancreatic ductal adenocarcinoma<br>This group will include 100 patients with pancreatic ductal adenocarcinoma, the clinical outcomes will be retrospectively assessed. at the same time 2 histopathological slides will be retrieved and stained for known markers as well as to P63. | Other: their will be no intervention in any of the groups, the study is retrospective<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 5 year overall survival | if the patient is alive or dead 5 years following the treatment | 5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| recurrence free survival | the recurrence of the disease within 5 years from the treatment | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
prognostic markers,Pancreatic ductal adenocarcinoma